Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.33 |
| ▸ | MIF | P14174 | 2/20 | 0.33 |
| ▸ | ARF6 | P62330 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22000871 | 0.90 | KDM4D (0.37) | PLATKDM4DPARP1CCNB2CDK1 | |
| SCHEMBL20565540 | 0.90 | KDM4D (0.33) | PLATKDM4DPARP1HSD11B1CCNB2 | |
| SCHEMBL20565498 | 0.87 | PARP1 (0.43) | PLATKDM4DPARP1 | |
| SCHEMBL20565113 | 0.87 | KDM4E (0.37) | KDM4DPARP1 | |
| SCHEMBL20564881 | 0.87 | BIRC5 (0.37) | PLATKDM4DMIFARF6PARP1 | |
| SCHEMBL20565460 | 0.86 | MIF (0.36) | PLATMIFARF6CCNB2CDK1 | |
| SCHEMBL20565415 | 0.79 | CA12 (0.38) | PLATCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL20565504 | 0.77 | ADORA3 (0.37) | KDM4D | |
| SCHEMBL20565117 | 0.76 | FEN1 (0.36) | PLATMIFHSD11B1CCNB2CDK1 | |
| SCHEMBL20564879 | 0.76 | MAPT (0.36) | PLATMIFCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | THE ROCKEFELLER UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | THE ROCKEFELLER UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3624805-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | Kapoor, Tarun, M. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213712-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | KAPOOR TARUN M (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148687-A1 | PYRAZOLOQUINAZOLINONE ANTITUMOR AGENTS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | PLAT 4647/4885KDM4D 4342/4885MIF 4455/4885 |
| US-11192893-B2 | Pyrazoloquinazolinone antitumor agents | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, TPD52L2 | PLAT 4647/4885KDM4D 4342/4885MIF 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.